Nib net profit up 3% to $67.6mln in the year to June 30

By Admin
The health insurer Nib has reported a 3% rise in the net profit of $67.6 million in the year to June 30, from $65.5 million in the previous year. The c...

The health insurer Nib has reported a 3% rise in the net profit of $67.6 million in the year to June 30, from $65.5 million in the previous year.

The company’s preferred measure of performance and its underwriting profit stood at $70.7 million. That was up 1.6% from the previous year on a like-for-like basis, said the company’s Managing Director Mark Fitzgibbon.

Dr. Fitzgibbon also said, “Despite the expected impact of the introduction of income testing of the federal government health insurance rebate, the market would keep growing.  He also said, “Increasingly, people don’t want to risk having to rely on the public health system.”

Dr Fitzgibbon stated, “We still see as our core strength our attraction in the under 40s market but we are very determined to grow the market share in the over 55s and corporate segments.” Further he added, “We also expect our international operations more and more important to our future earnings.”

Meanwhile, Dr. Fitzgibbon also stated, “The Company expects to make an underwriting profit in the range of $70 million to $75 million in the 2012-13 financial year.”

The health insurance company declared a fully-franked final dividend of 5 cents a share.

Nib is Australia’s fastest growing health fund that provides affordable health cover to more than 800,000 people nationwide. The company has recently become the first Australian health fund to demutualise and list on the Australian Securities Exchange.

Share

Featured Articles

WHO Health Chatbot Built on 'Humanised' GenAI

World Health Organisation's GenAI digital health tool is built using ‘AI humanisation’ tech & designed to ease burden on health workers & educate on health

Costco Weight-Loss Drugs Move Highlights US AOM Growth

Costco move to partner with online healthcare provider Sesame to provide members with weight-loss drugs including Wegovy signals US anti-obesity boom

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

As it's announced AstraZeneca's CEO Pascal Soriot's package could rise by as much as US$24mn we explore the history of the UK's most valuable business

US Academic Medical Centres 'Struggling' says McKinsey

Hospitals

J&J Community Initiatives Tackle US Healthcare Chasm

Medical Devices & Pharma

PitchBook: Healthcare Private Equity Deals see Decline

Health Insurance & Finance